Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn’s disease

Background and Aims: Anti-tumor necrosis factor mAb (i.e., adalimumab, ADA) is currently used in the treatment of patients with Crohn’s disease (CD). However, its regulation on fecal microbiota is still not fully understood. Methods: A retrospective analysis was conducted on 115 patients with CD who...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Liang, Lu, Zhanjun, Kang, Dengfeng, Feng, Zhongsheng, Li, Gengfeng, Sun, Mingming, Liu, Zhanju, Wu, Wei, Fang, Leilei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410713/
https://www.ncbi.nlm.nih.gov/pubmed/36034848
http://dx.doi.org/10.3389/fphar.2022.913720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410713/
https://www.ncbi.nlm.nih.gov/pubmed/36034848
http://dx.doi.org/10.3389/fphar.2022.913720

Ejemplares similares